EP3880176A4 - Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating diseases due to reduced bone density or cartilage loss and uses thereof - Google Patents
Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating diseases due to reduced bone density or cartilage loss and uses thereof Download PDFInfo
- Publication number
- EP3880176A4 EP3880176A4 EP19884612.3A EP19884612A EP3880176A4 EP 3880176 A4 EP3880176 A4 EP 3880176A4 EP 19884612 A EP19884612 A EP 19884612A EP 3880176 A4 EP3880176 A4 EP 3880176A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- sustained
- pharmaceutical compositions
- therapeutic agent
- treating diseases
- bone density
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000037182 bone density Effects 0.000 title 1
- 210000000845 cartilage Anatomy 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767254P | 2018-11-14 | 2018-11-14 | |
| PCT/US2019/061143 WO2020102323A1 (en) | 2018-11-14 | 2019-11-13 | Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating diseases due to reduced bone density or cartilage loss and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3880176A1 EP3880176A1 (en) | 2021-09-22 |
| EP3880176A4 true EP3880176A4 (en) | 2022-08-03 |
Family
ID=70730604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19884612.3A Pending EP3880176A4 (en) | 2018-11-14 | 2019-11-13 | Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating diseases due to reduced bone density or cartilage loss and uses thereof |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3880176A4 (en) |
| JP (1) | JP7431419B2 (en) |
| CN (1) | CN113056259A (en) |
| TW (1) | TWI729562B (en) |
| WO (1) | WO2020102323A1 (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101199505A (en) * | 2007-12-20 | 2008-06-18 | 沈阳药科大学 | Verapamil liposome and preparing method thereof |
| CN102406606A (en) * | 2011-11-29 | 2012-04-11 | 海南美大制药有限公司 | Solid quetiapine fumarate liposome preparation |
| US20130202686A1 (en) * | 2010-12-27 | 2013-08-08 | Terumo Kabushiki Kaisha | Liposome composition and process for production thereof |
| WO2017066726A1 (en) * | 2015-10-16 | 2017-04-20 | Merrimack Pharmaceuticals, Inc. | Stabilizing camptothecin pharmaceutical compositions |
| WO2017193139A1 (en) * | 2016-05-06 | 2017-11-09 | The Brigham And Women's Hospital, Inc. | Binary self assembled gels for controlled delivery of encapsulated agents to cartilage |
| US9877918B2 (en) * | 2011-03-25 | 2018-01-30 | Terumo Kabushiki Kaisha | Long-lasting controlled-release liposome composition and method for producing same |
| WO2020023445A1 (en) * | 2018-07-24 | 2020-01-30 | Taiwan Liposome Co., Ltd. | Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8658203B2 (en) * | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
| EP1855674B1 (en) | 2005-03-02 | 2014-07-16 | Merck Sharp & Dohme Corp. | Composition for inhibition of cathepsin k |
| AU2011353698B2 (en) * | 2011-01-05 | 2017-05-11 | Livon Laboratories | Methods of making liposomes, liposome compositions made by the methods, and methods of using the same |
| EP2537532A1 (en) | 2011-06-22 | 2012-12-26 | J. Stefan Institute | Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use |
| US9512083B2 (en) * | 2011-07-20 | 2016-12-06 | The General Hospital Corporation | Histone deacetylase 6 selective inhibitors for the treatment of bone disease |
| US9789062B2 (en) * | 2012-07-05 | 2017-10-17 | Tlc Biopharmaceuticals, Inc. | Methods of treating arthritis |
| KR102310786B1 (en) * | 2013-02-01 | 2021-10-12 | 존원 파마, 인코포레이티드 | Remote loading of sparingly water-soluble drugs into liposomes |
-
2019
- 2019-11-13 CN CN201980074616.4A patent/CN113056259A/en active Pending
- 2019-11-13 TW TW108141107A patent/TWI729562B/en active
- 2019-11-13 EP EP19884612.3A patent/EP3880176A4/en active Pending
- 2019-11-13 JP JP2021525745A patent/JP7431419B2/en active Active
- 2019-11-13 WO PCT/US2019/061143 patent/WO2020102323A1/en unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101199505A (en) * | 2007-12-20 | 2008-06-18 | 沈阳药科大学 | Verapamil liposome and preparing method thereof |
| US20130202686A1 (en) * | 2010-12-27 | 2013-08-08 | Terumo Kabushiki Kaisha | Liposome composition and process for production thereof |
| US9877918B2 (en) * | 2011-03-25 | 2018-01-30 | Terumo Kabushiki Kaisha | Long-lasting controlled-release liposome composition and method for producing same |
| CN102406606A (en) * | 2011-11-29 | 2012-04-11 | 海南美大制药有限公司 | Solid quetiapine fumarate liposome preparation |
| WO2017066726A1 (en) * | 2015-10-16 | 2017-04-20 | Merrimack Pharmaceuticals, Inc. | Stabilizing camptothecin pharmaceutical compositions |
| WO2017193139A1 (en) * | 2016-05-06 | 2017-11-09 | The Brigham And Women's Hospital, Inc. | Binary self assembled gels for controlled delivery of encapsulated agents to cartilage |
| WO2020023445A1 (en) * | 2018-07-24 | 2020-01-30 | Taiwan Liposome Co., Ltd. | Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof |
Non-Patent Citations (8)
| Title |
|---|
| CHEN J ET AL: "Preparation and pharmacokinetic investigation of propranolol-loaded elastic liposomes composed of DP-PC and SPC", CHINESE PHARMACEUTICAL JOURNAL, ZHONGGUO YAOXUEHUI ZHUBAN CHUBAN. ZHONGGUO-YAOXUE-ZAZHI BIANJI WEIYUANHUI, CN, vol. 48, no. 20, 22 October 2013 (2013-10-22), pages 1761 - 1765, XP009534476, ISSN: 1001-2494 * |
| EL-MEZAYEN NESRINE S ET AL: "Hepatic stellate cell-targeted imatinib nanomedicineversusconventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 266, 28 September 2017 (2017-09-28), pages 226 - 237, XP085292753, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2017.09.035 * |
| KIM HYEONGSEOK ET AL: "Anti-inflammatory effect of quetiapine on collagen-induced arthritis of mouse", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 678, no. 1, 23 November 2011 (2011-11-23), pages 55 - 60, XP028891080, ISSN: 0014-2999, DOI: 10.1016/J.EJPHAR.2011.12.017 * |
| SATO TSUYOSHI ET AL: "Donepezil prevents RANK-induced bone loss via inhibition of osteoclast differentiation by downregulating acetylcholinesterase", HELIYON, vol. 1, no. 1, 1 September 2015 (2015-09-01), GB, pages e00013, XP055935707, ISSN: 2405-8440, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939821/pdf/main.pdf> DOI: 10.1016/j.heliyon.2015.e00013 * |
| See also references of WO2020102323A1 * |
| TAKAMATSU AKIRA ET AL: "Verapamil Protects against Cartilage Degradation in Osteoarthritis by Inhibiting Wnt/[beta]-Catenin Signaling", PLOS ONE, vol. 9, no. 3, 21 January 2014 (2014-01-21), pages e92699, XP055935688, DOI: 10.1371/journal.pone.0092699 * |
| TORU HIRAGA ET AL: "Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals", INTERNATIONAL JOURNAL OF CANCER, vol. 124, no. 1, 1 January 2009 (2009-01-01), US, pages 215 - 222, XP055292283, ISSN: 0020-7136, DOI: 10.1002/ijc.23903 * |
| ZHANG XINGGUANG ET AL: "Propranolol Prevents Osteoporosis and up-regulates Leptin in Ovariectomized Rats", IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH : IJPR, 1 January 2013 (2013-01-01), Iran, pages 557 - 562, XP055935721, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813260/pdf/ijpr-12-557.pdf> [retrieved on 20220627] * |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI729562B (en) | 2021-06-01 |
| EP3880176A1 (en) | 2021-09-22 |
| JP2023510658A (en) | 2023-03-15 |
| TW202031247A (en) | 2020-09-01 |
| WO2020102323A1 (en) | 2020-05-22 |
| CN113056259A (en) | 2021-06-29 |
| JP7431419B2 (en) | 2024-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004025B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| EP3954395A4 (en) | Pharmaceutical composition for muscle disease treatment | |
| IL275754A (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| IL288375A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| EP3753557A4 (en) | Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases | |
| IL279397A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| IL287796A (en) | Compositions and methods for the treatment of atpase-mediated diseases | |
| EP4000609A4 (en) | Pharmaceutical composition for preventing or treating bone diseases | |
| KR102462548B9 (en) | CD300c PHARMACEUTICAL COMPOSITION COMPRISING INHIBITORS OF CD300c's EXPRESSION OR ACTIVATION FOR PREVENTING OR TREATING OF CANCER | |
| GB202010464D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| GB201907558D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| EP3877383A4 (en) | Compounds and compositions for the treatment of respiratory diseases | |
| EP3826615A4 (en) | Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof | |
| EP3852760A4 (en) | Matter of composition, synthesis, formulation and application of fl118 platform positions 7 and 9-derived analogues for treatment of human disease | |
| EP3829539A4 (en) | Sustained-release compositions comprising a therapeutic agent for treating depression or anxiety and uses thereof | |
| SG11202007082PA (en) | Composition used for therapeutic treatment of skin disease | |
| EP3881843A4 (en) | Prophylactic or therapeutic agent and medicinal composition for il-31-mediated disease | |
| EP3880176A4 (en) | Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating diseases due to reduced bone density or cartilage loss and uses thereof | |
| IL285751A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| EP3925623A4 (en) | Medicinal composition for preventing or treating bone diseases | |
| IL281080A (en) | Compositions comprising a selenite-containing compound and a pharmaceutically acceptable acid for treating human papillomavirus infections | |
| KR102276379B9 (en) | IF1 ATPase inhibitory factor 1 Composition for Preventing or Treating Bone Diseases Comprising IF1 | |
| EP4197557A4 (en) | Pharmaceutical composition for preventing or treating bone diseases | |
| EP4000622A4 (en) | Pharmaceutical composition for preventing or treating bone diseases | |
| TWI859508B (en) | Pharmaceutical compositions for the treatment of bone diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20210512 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20220706 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/26 20060101ALI20220630BHEP Ipc: A61K 47/02 20060101ALI20220630BHEP Ipc: A61P 35/00 20060101ALI20220630BHEP Ipc: A61K 31/496 20060101ALI20220630BHEP Ipc: A61K 9/00 20060101ALI20220630BHEP Ipc: A61K 31/495 20060101ALI20220630BHEP Ipc: A61K 9/127 20060101AFI20220630BHEP |